NCT02676778 - Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 28, 2016

Primary Completion Date

April 26, 2019

Study Completion Date

April 26, 2019

Conditions

Peripheral T-cell LymphomaCutaneous T-cell Lymphoma

Interventions

DRUG

E7777

Trial Locations (20)

Eisai Trial Site #1, Nagoya

Eisai Trial Site #2, Nagoya

Eisai Trial Site #1, Kashiwa

Eisai Trial Site #1, Ōta

Eisai Trial Site #1, Kobe

Eisai Trial Site #1, Tsukuba

Eisai Trial Site #1, Isehara

Eisai Trial Site #1, Sendai

Eisai Trial Site #1, Kurashiki

Eisai Trial Site #1, Suita

Eisai Trial Site #2, Suita

Eisai Trial Site #1, Hamamatsu

Eisai Trial Site #1, Yamagata

Eisai Trial Site #1, Bunkyo-ku

Eisai Trial Site #1, Chuo-ku

Eisai Trial Site #1, Koto-ku

Eisai Trial Site #1, Fukuoka

Eisai Trial Site #1, Kagoshima

Eisai Trial Site #1, Kyoto

Eisai Trial Site #1, Okayama

All Listed Sponsors

lead

Eisai Co., Ltd.

INDUSTRY